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ABSTRACT
The objective of this study is to synthesize and characterize antimicrobial, bio-polymer
based silver nanomaterials composite coatings, for use in chronic indwelling medical devices,
and bioscaffolds. The coatings and bioscaffolds are comprised of novel biomass mediated silver
nano particles (SNP) that are biocompatible, highly concentrated, highly pure, cost-effective,
polydispersed and compatible with a range of polymer systems applicable for use with existing
chronic indwelling medical devices.
This thesis is divided into three main chapters. In Chapter 1, detailed review on the need
for antimicrobial nanocomposite coatings for chronic indwelling medical devices along with
different SNP synthesis and characterization methods is provided. In Chapter 2 a comprehensive
description of biocompatible/bioresorbable poly (L-lactide) (PLLA) based thin film coatings
comprised of novel 25-75 nm silver nano particles SNP is provided. The particle and film
morphology is characterized using Transmission Electron Microscopy (TEM), Atomic Force
Microscopy (AFM) and UV-Visible Spectroscopy. The release rate of SNP is profiled by
Thermogravimetric Analysis (TGA) and Inductively Coupled Plasma Optical Emission
Spectrometer (ICP-OES). These coatings, suitable for chronic indwelling devices, drastically
reduce the microbial biofilm formed by Staphylococcus aureus and Escherichia coli by 3-5 log
reduction. This chapter details the synthesis of PLLA cast-coatings and the procedure to embed
SNP, an antimicrobial agent, at a range of concentrations to identify an optimal SNP
concentration of 700-800 ppm that efficacious and non-cytotoxic to human epithelial carcinoma
cells (HeLa). Chapter 3 explains the procedure of making biocompatible/bioresorbable PLLAPEG co-polymer block bioscaffolds designed to degrade and resorb at a controlled rate while
providing a suitable substrate for tissue regrowth. The antimicrobial properties of these porous

xii

bioscaffolds are tested across varying concentrations of biomass mediated SNP, to determine an
efficacious antimicrobial concentration. The bioscaffolds are efficacious as it reduces the
Staphylococcus aureus and Escherichia coli biofilm by 92.5- 99.9%, respectively, at an
antimicrobial SNP concentration of 800ppm.

xiii

CHAPTER 1. INTRODUCTION
New Medicare/Medicaid regulations being phased in starting in 2008 have drastically
reduce the reimbursement to healthcare providers for services provided related to treating
healthcare associated conditions. Of specific concern to indwelling device manufactures are
regulations that curtail compensation for septicemias, urinary tract infections associated with
Foley catheter therapy and certain surgical site infections. According to the Pennsylvania Health
Cost Containment Health Council (PHC4), in 2006, the average additional cost to treat a patient
who acquired a surgical site infection was $191,872 of which only ~27% of the established
charges were reimbursed [1]. Many indwelling medical devices now incorporate traditional
antibiotics and/or inorganic antimicrobial compounds to reduce the risk of infection associated
with implantation. Several of these agents, which are associated with Healthcare Acquired
Infections (HAI), have become increasingly resistant to traditional antibiotics. Bacterial stains
such as Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant
Enterococcus (VRE) have demonstrated broad resistance to beta-lactam and glycopeptides based
antibiotics and have been frequently associated with indwelling devices resulting in difficult to
treat infections[2]. A variety of active and passive strategies have been employed to impart
antimicrobial properties to the materials used in the construction of indwelling devices including;
antibiotics [3], inorganic salts [4-5], inorganic nanomaterials [6-7] and organic compounds [89].While these strategies have produced satisfactory results for acute indwelling devices such as;
professional wound dressings [10], central venous catheters[11] and endotracheal tubes[12-14];
none of these approaches to incorporating an antimicrobial has yielded an optimized solution for
chronic indwelling device environments. Among the device based antimicrobial solutions that
are currently commercially available silver, in a number of forms, has a successful history of safe
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and efficacious use against a broad spectrum of gram-positive and gram-negative microbial
agents [15-17]. Recent advances in materials development have created novel nanoscale forms of
silver metal that present potential advantages in efficacy, ease of integration and safety when
compared to ionic silver or bulk metal delivery vehicles [6-7, 18-20].
This study evaluates the applicability of a silver nanomaterial based antimicrobial
compound as a chemo-prophylactic agent in bioresorbable/biocompatible thin film coatings and
biological scaffolds. It determines the concentrations and contact times required for in vitro
elimination of known titers of two model organisms, Staphylococcus aureus and Escherichia
coli. Silver release rate and nanoparticle erosion as a function of particle concentration and thin
film composition is characterized, along with bioresorbable films/scaffolds response to exposure
to simulated physiological solution. The values obtained provides a baseline for follow-on invitro and in vivo challenge trials, cytotoxicity studies and is used to assess how silver
nanoparticles can best be implemented in both antimicrobial coatings for chronic indwelling
devices and tissue scaffolds.
1.1 Existing Antimicrobial Compounds
1.1.1

Silver as an Antimicrobial Agent
Silver is an oligodynamic antimicrobial compound, meaning that exposure to relatively

low concentrations of the metal can result in substantial reduction of viable microbial organisms.
The ionic form of the compound, Ag+, has been identified as the primary active agent [21],
although some recent research indicates that the nanoscale metal form of the compound may
have some unique antimicrobial attributes [22]. Various silver compounds have been used as
antimicrobial agents in many healthcare related applications including; pathogen control,
prophylaxis and therapeutic treatments. Salts [23-26], zeolites [27-29] and thin film metal

2

coatings [30] have demonstrated some utility as silver ion sources for medical devices, but
concerns regarding cost, performance and safety have limited the broader adoption of these
delivery vehicles in indwelling device applications.
1.1.2 Silver Bearing Salts
Silver bearing salts, specifically, silver nitrate, silver halides and silver sulfadiazine
(SSD) have been used as an antimicrobial agent in applications ranging from burn treatment to
catheter systems. The exact mechanism of silver and its salts on the microbes is still not known
but the possible mechanism of metallic silver, silver ions and silver nanoparticles have been
suggested after looking at the morphological and structural changes in the bacterial cells [31].
The silver interacts with thiol group compounds found in the respiratory enzymes of bacterial
cells and binds to the bacterial cell wall and cell membrane, inhibiting the respiration
process[32]. In the case of E. coli, it acts by inhibiting the uptake of phosphate and releasing
phosphate, mannitol, succinate, proline and glutamine from E. coli cells [33-37]. The replication
of DNA is effectively conducted when the DNA molecules are in relaxed state and loses its
replication ability when in condensed form. When the silver ions penetrate inside the bacterial
cells, DNA molecule condenses reducing the rate bacterial replication. It has also been reported
that heavy metals react with proteins by interacting with the thiol group deactivating
proteins[31].
Silver nitrate is a highly water soluble compound that has been used historically in the
treatment of burns and as a prophylactic to reduce the transmission of gonorrhea to new born
infants during birth[38]. Silver nitrate has not been used extensively as a device delivered
antimicrobial, as its high water solubility and low chemical and thermal stability result in
relatively short duration of release and challenges in device design and incorporation.
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Additionally, studies comparing wounds treated with silver based antimicrobials have
demonstrated that silver nitrate, compared to other silver forms, significantly retards the reepithialization and neovascularzation of wound beds [24, 39]. Two halide forms of silver; silver
chloride and silver bromide, have been explored as sources of Ag ion for medical device coatings
but poor solubility and poor thermal stability, compared to other ionic forms, have limited their
broader use in medical device applications [24, 40-41].
In the 1970’s silver sulfadiazine (SSD), a salt derivative of a sulfa drug compound, was
characterized and formulated for use in topical creams and ointments to provide a more
efficacious and stable ionic silver delivery option for the treatment of burns and other chronic
wounds[42]. More recently, the use of SSD as an active agent has been expanded beyond topical
applications including incorporation in devices such as central line catheters and professional
wound care dressings and packings [26, 43]. The mechanism of action of SSD is distinct from
silver nitrate and silver halide compounds as it acts by disrupting the organism’s cell wall and
releasing ionic silver through interaction with physiological solutions[42]. The compound’s poor
solubility in aqueous environments and chemical instability has prevented its broader use in
device based delivery systems. While SSD is less cytotoxic than silver nitrate, it is still
significantly more toxic than many other commonly used antiseptics and antibiotic compounds,
it can prolong wound healing and has been implicated in cases of renal failure [44-46].
1.1.3 Silver Zeolites and Glasses
Silver bearing zeolites and glasses, which entrap Ag ion in ceramic crystal or amorphous
glass carriers, are the second most common source of Ag ion used in the manufacture of medical
devices. Both the zeolites and glass compounds are relatively large, ~2-200 m hydrophilic
particles, but each compound has distinctly different mechanisms for silver ion release. Silver
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zeolites are typically composed of mesoporous aluminosilicate or zirconium phosphate which
entrap Ag ion within the nanoscale pores in the crystal structure. Zeolites release Ag + into
solution through a kinetically favorable ion exchange process with Na + or K+, ions which are
ubiquitous in physiological environments. Exposure of high salinity physiological solutions
typically results in an initial bolus of Ag ion release and rapid exhaustion of the bioavailable
silver ion within the device. The micron scale ceramic carrier is largely inert and not
biodegradable, end of life cycle analysis indicates that substantial amounts of silver in zeolites
are not bioavailable and remain sequestered within the crystal structure. [29]
Unlike zeolites, silver glass particles are amorphous and are typically composed of
unstable, silver doped silica and phosphate compounds [47-48]. Silver doped glass or “bioglass”,
as it is often referred, releases silver ion through a surface mediated corrosion process. The
relatively large size of the particles and the chemical stability of the silver oxide form in glass
tend to reduce the bioavailability of silver ion. Thus requiring high concentrations of bioglass, in
the parts-per-thousand range, to achieve reasonable microbial kill rates[48]. The large size and
slow corrosion rate of the bioglasses limit their use in bioresorbable thin film coatings. Zeolites
and bioglasses share some common features; the silver in both classes of compounds tend to
photo-reduce on exposure to light, reducing the amount of bioavailable silver[49]. Also, the
hydrophilic nature of the particle surface reduces the solubility of both types of materials in
hydrophobic polymer and solvent systems.
1.1.4

Other Silver Sources
Bulk metal silver coatings have been used to impart antimicrobial properties to several

types of medical devices including; catheters, endotracheal tubes and heart valves. The silver
coated heart valve device produced by St. Jude Medical, is notable in that the device’s bulk silver
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coating promoted the onset of endocarditis in tissue immediately in contact with the valve
material leading to device rejection[50-51]. This unexpected cytotoxicity associated with long
term exposure to bulk silver coated implants has limited its use to device designed for acute
applications.
The recent commercial availability of metallic, nanoparticle silver polymer additives has
created a renewed interest in silver based antimicrobials [6, 43, 52]. Advances in synthetic
techniques used for particle production have greatly reduced cost, improved yields, and
diversified the available particle chemistries and morphologies [53-58]. Shapes such as rods,
spheres, pyramids and other polygons can be combined with a myriad of chemical functionalities
to create a wide window of particle solubility and reactivity. This highly flexible nanoscale form
of metallic silver potentially addresses many of the limitations of ionic silver delivery systems
that have restricted their use as an antimicrobial in the design and manufacture of chronic
indwelling devices.

SNP provides a thermally, chemically and photostable reservoir of metal

atoms that are uniquely suited to polymer composite formation while remaining available for
conversion to the active ionic compound upon exposure to physiological solutions. SNP show
efficient antimicrobial property compared to other salts due to their extremely large surface area,
which leads to better contact with microorganisms [31].
Our novel biomass medicated synthesis and concentration/purification method allows for
the synthesis of high purity, biocompatible, nanomaterial powders and colloidal solutions with
tunable chemical properties. This SNP synthesis method produces metal nanoparticles with a
size distribution from 25-75 nm. By careful choice of capping

surfactants and

bioresorbable/biocompatible stabilizing agents the silver ion release profile and particle
dissolution rate can be predictably modified, allowing fine control of the antimicrobial efficacy
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and particle lifetime in a physiological environment. Additionally, by combining SNP’s into a
bioresorbable, thin film coatings we will create a further degree of freedom for influencing
particle longevity and silver ion release. In an effort to explore the breadth of silver ion release
capabilities, NanoHorizons Inc. (State College, PA) prepared alginate based wound dressings
with varying compositions of SNP and compared silver release to commercially available, silver
containing dressings (Fig 1.1). In the case of alginate substrates NanoHorizons found a nearly
linear relationship between silver nanoparticle content and silver elution rate, which allowed us
to tune the silver release profile to both match and exceed each of the commercially devices, thus
demonstrating the degree of control which nanomaterial enhanced biocompatible composites can
afford device designers.

Figure 1.1. Comparison of silver elution vs. time from commercially available silver
containing dressings and SNP-alginate composite dressings
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Based on this method, several commercial compounds have been developed and are in
use in a variety of applications such as in hospital beds, medical foams, apparel and industrial
textiles, sanitary ceramics and cleaning products.
1.2 Method Selection
The applicability of silver nanomaterials in various applications has attracted considerable
recent interest. Some of their applications include being used as catalysts [59-63], as
photosensitive components [64], in photocatalysis [65-68], in chemical analysis [69], as probes
for enhanced Raman spectroscopy, and as biocidal agents [70-78]. The large surface area and
higher reactivity of SNP when compared to bulk solids allow the particles to exhibit
extraordinary chemical, physical and biological properties. With wide range of potential
applications, it is not surprising that many authors have reported various methods to synthesize
powder noble metals with improved morphology and smaller particle size.
Some of the broadly categorized SNP syntheses include reduction methods, sol-gel
processing, high pressure spurting, plasma synthesis, chemical vapor synthesis (CVS), and using
microorganisms for the biosynthesis of metal NP.
1.2.1 Reduction Methods
SNP can be produced by reducing agents such Sodium tetrahydridoborate NaBH 4[79],
HCHO/NaOH/Na2CO3 [80] , a combined reduction by tri-sodium citrate and formaldehyde
sulfoxylate (SFS) [81], tetrakis hydroxymethyl phosphonium chloride, citric acid hydrazine
hydrate and solvents like DMF, Ethylene glycol.
In 1979, silver sols were prepared by reduction of AgNO 3 in an excess solution of
NaBH4[82]. The solutions of silver salts were mixed rapidly and vigorously in order to aid
monodispersity. Pyridine molecules adsorbed on the silver sol particles caused intense Raman
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scattering. The sols were yellow and displayed a single visible extinction band near 400 nm by
Raman spectra. The silver particles were substantially smaller than the wavelength of light and
as indicated by transmission electron microscopy, the size of the particle diameter was roughly in
the range 1-50 nm [79]. The sols were stable and there was no precipitation or change in color on
standing for several weeks.
Formaldehyde can also be used as a reducing agent for preparing nanoscale silver
particles. In this synthesis, silver nitrate solution is used as the source of ion. The surfactant
polyvinyl-pyrrolidone (PVP), a protective agent, is then added to AgNO 3 and the metal is
reduced using a formaldehyde solution. To increase the rate of the reaction, pH is increased by
the addition of an alkaline solution consisting of NaOH and/or Na 2 CO3 which results in a faster
reduction. This synthesis produces well-dispersed spherical shaped crystalline silver particle with
7–20 nm size [80].
The stoichiometric reaction of this process can be summarized as follows:
2Ag+ + HCHO + 3OH−

2Ag + HCOO− + 2H2O (1)

2Ag + + HCHO + OH −

Ag + HCOOH + 1/2H2 (2)

Direct large-scale synthesis of SNP is conducted by various reduction chemical methods
but using mild reducing agent, such as formaldehyde SFS provides good particle morphology
and results in fine silver powder [81].
In this method for the synthesis of SNP, an aqueous solution of tri-sodium citrate was
added to an aqueous solution of silver nitrate. The drop-wise addition of aqueous sodium
formaldehyde sulphoxylate and continuous stirring at room temperature formed a dark gray
precipitate, which can be filtered off, washed with methanol and dried. Scanning Electron
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Microscopy (SEM) images indicate 30-50 nm spherical and agglomerated SNP due to the
presence of surfactants/capping agents.
1.2.2 Sol-gel Process
The sol-gel technique is low temperature method for synthesizing organic or inorganic
amorphous materials. It is based on hydrolysis and condensation reactions of organometallic
compounds in alcohol solutions [83]. Many metal particles including gold [83-84], copper [85],
platinum, palladium [86] and silver [87] have been prepared in glassy matrices by the sol-gel
method.
For the creation of stable silver metal nanoparticles, AgNO 3 is dissolved in the precursor
sol that contains TetraEthoxy OrthoSilane (TEOS) and Methyl- TriEthoxy OrthoSilane
(MeTEOS). Soda lime glass slides can be added in the precursor sol and AgCl containing sol gel
glasses are prepared. When these films are heated to 600 0C, stable silver metal nanoparticles are
created that are 2-21 nm in size as calculated from X-ray diffraction [82]. This method produces
large clusters of SNP of inconsistent size.
1.2.3 Chemical Vapor Synthesis (CVS)
Recently, CVS has become popular tool for producing highly pure, ultrafine and unagglomerated nano-crystalline powders. Many chemical vapor methods have been developed
which take advantage of various conditions to prepare SNP. Some of the various CV methods
include sonic-jet corona discharge [88-89], electrospray-assisted CVD process [90] and
supersonic nozzle expansion method [91].
In sonic-jet corona discharger method, sonic-jet corona ionizer is heated by an infrared
furnace and an electric field is applied. Charged nanoparticles are deposited on the substrate

10

electrode in the CVD nanoparticle generator by the help of an electric field after ionized
molecules are introduced in the furnace.
The electrospray-assisted CVD reactors consist of an electrospray source, a tube-type
CVD furnace and an electrostatic sampler. Liquids are supplied into the capillary by a high
resolution syringe pump and a high voltage is applied to the capillary through a high DC voltage
source. Electric current carried by electrospray and the stability of the spray is monitored
visually, in this process changes in the voltage could result in multiple jets of the liquid. NPs
were produced by the thermal decomposition of the precursor vapors in the reactor.
Recently, supersonic nozzle expansion method (rapid decrease in temperature and
density) with corona discharge ions was used for synthesizing SNP. In the particle formation
step, the high cooling rate of condensable vapor results in a large supersaturation for the
nucleation rate. The nucleation and growth of the SNP occurs after the expansion region in the
supersonic nozzle, where corona discharge ions are applied, as the nuclei for nanoparticles, to
impart charge and modulate agglomeration.
Overall, CV methods produce NP from the vapor phase in a well controlled temperature
zone of a hot wall reaction tube. These processes typically produce agglomerated NP due to their
Brownian coagulation in the CVD reactor. Although latest CVD methods have produced
nonagglomerated, smaller sized and charged nanoparticles [91].
1.2.4 Biological Approach
With an increased demand to develop clean, nontoxic and environmentally friendly NP
synthesis methods, many researchers have started looking at biological systems for inspirations
[56]. There are many examples both in the plant and animal kingdom of unicellular and
multicellular organisms that produce inorganic materials either intra- or extracellularly [92-93].
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Some of them include magnetotactic bacteria (synthesize magnetite nanoparticles)[94-95],
diatoms (synthesize siliceous materials) [96-97], S-layer bacteria (produce gypsum and calcium
carbonate layers) [98-99] and fungus Verticillium (synthesize aqueous Ag+ ions) [100].
The biological synthesis of silver-based 200 nm crystals in the periplasmic space of
Pseudomonas stutzeri AG259 was reported in 1999 [36, 101]. This bacterium strain was
originally isolated from silver mine[36]. In this method, the cells are cultured in the presence of
high concentrations of silver salts. They are then harvested, fixed, distilled and polymerized.
Ultrathin sections are stained and visualized under microscope.
There are many other methods of synthesizing SNP including genetically engineered
human L subunit ferritin [102], high pressure spurting[103], plasma spray methods [104],
supercritical fluids (SCFs) [105] and etc. Although many of these methods have succeeded in
synthesizing nonagglomerated, pure, small size and stable SNP, there still exists a room for
improvement in the design of polymer based SNP synthesis.
1.3 Characterization of Silver Nano Particles
The inclusion of silver nanoparticles into biocompatible polymers presents us with the
analytical challenge of characterizing thin film. Many analytical methods have been published to
characterize and confirm the presence of nanoparticles in the polymers. These methods outline
the chemical composition and physical characteristics of the nanomaterials [106].
1.3.1 Atomic Force Microscopy (AFM)
Initially, AFM was introduced as imaging tool [107] as it provides high resolution, threedimensional images and helps in detailing surface topography. Recently it has been widely used
for the investigation of nanoparticle-doped materials and surface biofouling. It has also been
used to examine nanoparticle deposition on silicon substrates, and the morphology of these
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nanoparticles was studied [108]. Several publications have also used AFM to confirm the
morphology and size distribution of silver nanoparticles [109]. It has several advantages terms of
resolution, speed and ease of sample preparation when compared to other when compared to
cryo-electron microscopy and X-ray crystallography techniques [110].
For our synthesis AFM has been used to determine the organization, shape and size of
SNP.
1.3.2 Transmission Electron Microscopy (TEM)
TEM is also an analytical tool for determining the morphology and arrangement of
nanoparticles comprised materials. Several studies have utilized TEM as a characterization
method for different nanoparticles including SNP [111].
Embedded SNP, in ultra thin specimen, can be visualized by TEM [112] and serves as
one of our major characterization tools. It enables us to visualize and characterize the
morphology and distribution of SNP embedded in the biocompatible polymer-based coatings.
1.3.3 Scanning Electron Microscopy (SEM)
SEM is also an analytical tool that uses a focused beam of high-energy electrons to
generate a variety of signals at the surface of solid specimens. Unlike TEM, it allows the surface
structure of the sample to be studied at high resolutions, enabling characterization of external
morphology (texture), chemical composition, and crystalline structure and orientation of solid
materials.
Due to its high resolution we will use SEM to characterize and morphologically define
the biocompatible/biogradable PLLA co-polymer antimicrobial bioscaffolds that will be tested
against gram-positive and gram-negative bacteria.
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1.3.4 UV-Visible Spectroscopy
UV-visible spectroscopy is a very simple and quick method for characterizing noble metal
nanoparticles and is mostly used to confirm the presence of nanoparticles in a liquid. It is not
capable of providing detailed information regarding NP size distribution when compared to
microscopy based analysis techniques but is a semi-quantitative method for determining the
presence and size distribution of NP. UV-Vis can also serve as an indicator of material
deterioration and is a qualitative method for indicating the presence of nanoparticles in the
polymer.
The breadth of the UV-visible chromatogram peak, obtained from SNP, will indicate the size
distribution of SNP but morphology has to be confirmed using different imaging methods. The
sample preparation for this method is very simple and will enable us to monitor the effectiveness
of the silver nanomaterial and adhesion of SNP to the biocompatible polymer.
1.4 Silver Content Analysis
Determining the silver content in these NP composites is critical to the design of effective
antimicrobial coatings. The silver content of polymers is typically proportional to the ion elution
rate and the content analysis will help in tuning the silver concentration to achieve maximum
efficacy of the biocompatible/bioresorbable polymer-based coatings and scaffolds. Some of the
methods that comply with our needs and are available to use are Thermogravimetric Analysis
(TGA) and Inductively Coupled Plasma-Optical Emission Spectrometer (ICPOES).
1.4.1 Thermogravimetric Analysis (TGA)
TGA is commonly used in research and testing to determine the mass of inorganic and
organic components in materials by measuring the characteristic of weight change of a material
in relation to changes in temperature. Synthesized copper, silver and alumina nanocomposites
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have been characterized by thermo gravimetric analysis to study the composition of the metal
nanoparticles’ percentage contained in the polymer/composite [113]. The weight loss curve, after
curve smoothing and other operations, can be used to find the point of deflection.
For our SNPs, TGA serves as one of our major characterization tools to determine the
percent of silver particles in the polymer. Additionally, TGA can also provide information
related to the spatial conformation of the silver content and the chemical state of the Ag atoms in
the SNP solution [114].
1.4.2 Inductively Coupled Plasma Optical Emission Spectrometer (ICPOES)
ICP-OES (Inductively Coupled Plasma-Optical Emission Spectrometer) is one of the
most common analytical methods for determining silver content as it has high sensitivity, high
precision, and capable of determining range of metals and several non metals at concentrations
range from a several percent to ppb levels [115].
In this study, ICPOES analysis is used to monitor the release of SNP particles and ions
from the biocompatible/bioresorbable polymer based coating after being treated with bacteria.
The analysis enables us to quantify the release of SNP from the coatings in a time-based study
and plot the release profile of SNP.
1.5 Material Selection
Increasingly during the past 40 years research in the field of biocompatible materials has
been directed to the development and characterization of “bioerodible” or “bioresorbable”
materials. These are materials which can be degraded and excreted from the body over an
extended period of time ranging from days to years have and have been used in a variety of
applications including medical device coatings [116] sutures and tissue scaffolds[117]
A variety of “natural” (occurring in nature) and synthetic materials have been identified
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or developed which broadly meet the criteria to be considered bioresorbable or bioerodible.
Some of the broad categories include aliphatic esters, chitosan, aliginates, polyhydroxy acids and
poly (tyrosine-carbonates)[118]. Of these compounds the material and chemical properties of
aliphatic esters such as poly-L-lactic acid (PLLA), poly-L-glycolic acid (PLGA), make them of
interest for orthopedic device applications.

The in-vivo degradation processes of these

compounds have been well described and while there are some reports of the onset of late stage
inflammation responses, these have been attributed to high molecular weight particles released
from highly crystalline substrates [119-120].
The accepted guidelines for the selection of an appropriate material include: that the
material is broadly biocompatible and the polymer coating material must degrade and resorb at a
controlled rate. For a tissue scaffold the polymer should also provide a suitable substrate for
tissue regrowth and have regulatory approval or have the potential to gain approval [121].
Additionally, in the case of coatings for orthopedic implants the material must have the
appropriate hardness, modulus and adhesion strength to survive the implantation procedures and
use.
1.5.1 Poly (L-lactide)
There is a limited pool of biocompatible polymers that are also bioresorbable and can be
used for chronic indwelling medical devices. Chitosan, PLLA, PLGA and collagen are few
examples that qualify as potential substrates for our thin film coatings and bioscaffolds.
Poly (L-lactide) (PLLA), aliphatic ester, has been widely used in the biomedical industry
as a major component of biodegradable sutures, medical device coatings and bone fixation nails
and screws [122]. The compound is well characterized and the degradation of PLLA is
dominated by nonenzymatic hydrolysis of polymer chains catalyzed by carboxylic acid chain
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ends of polymers. This degradation process results in non-toxic monomers and oligomers of
lactic acid [123]. The degradation rate of PLLA is dependent on the molecular weight of the
polymer, typically high molecular weight PLLA has been used in orthopedic surgery [124]. For
these reasons, PLLA has been selected as the polymer of choice in our study. PLLA of different
molecular weights (~40,000 to 1000, 000) are commercially available. To create the composite
PLLA thin film coatings and PLLA-PEG bioscaffolds we selected PLLA with average molecular
weight of 100,000-150,000.
1.5.2 Polyethylene Glycol (PEG)
Polyurethanes are a class of hydroxyl group containing polymers that consist of a chain
of organic units joined by urethane. In recent years, biocompatible material research has been
focused on using resorbable and degradable polyurethanes for tissue regeneration including
cardiovascular repair, ligament reconstruction, cancellous bone regeneration, and drug delivery.
Generally, polyurethanes are developed by labile moieties, such as caprolactone, lactides,
hydroxybutyric acid, saccharide and amino acids that can be broken enzymatically or chemically
by hydrolysis [125]. PEG’s chemical functionality, flexible hydrophilic chain, low toxicity and
low immunogenicity [126-127], have made it an ideal option as one of the polymer constituents
of PLLA-PEG co-polymer with novel SNP to be used as antimicrobial bioscaffolds [128].
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CHAPTER 2. BIOCOMPATIBLE/ BIORESORBABLE POLYMER BASED
SILVER COATINGS FOR CHRONIC INDWELLING MEDICAL
DEVICES
2.1 Introduction
The chronic indwelling medical devices market is rapidly expanding and the use of these
devices is often complicated by infections with biofilm-forming microbes that are resistant to
various antimicrobial agents. Several antimicrobial agents have been synthesized for various
applications including use in acute indwelling devices but the need of industrially relevant,
biocompatible, cost-effective and highly concentrated antimicrobial agents for chronic
indwelling devices remains.
Biofilms are formed when bacteria excrete glue-like substance composed of a matrix of
excreted polymeric compounds called exopolysaccharide (EPS). This provides bacteria a
generalized method to adhere broad spectrum of materials including, metals, polymers and
medical implants. To combat the biofilm reduction, a variety of active and passive strategies
have been employed to impart antimicrobial properties to the materials used in the construction
of indwelling devices including; antibiotics [1-2], inorganic salts [3-4], inorganic nanomaterials
[5-6] and organic compounds [7-8].While these strategies have produced satisfactory results for
acute indwelling devices such as; wound dressings [9], central venous catheters[10] and
endotracheal tubes [11-13]; none of these approaches to incorporating an antimicrobial has
yielded an optimized solution for chronic indwelling device environments. Many indwelling
medical devices now incorporate traditional antibiotics and/or inorganic antimicrobial
compounds to reduce the risk of infection associated with implantation. Several of these agents,
which are associated with Healthcare Acquired Infections (HAI), have become increasingly
resistant to traditional antibiotics. Bacterial stains such as Methicillin Resistant Staphylococcus
Aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE) have demonstrated broad
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resistance to beta-lactam and glycopeptides based antibiotics and have been frequently
associated with indwelling devices which have resulted in difficult to treat infections[14].
Among the device based antimicrobial solutions that are currently commercially available
silver, in a number of forms, has a successful history of safe and efficacious use against a broad
spectrum of gram-positive and gram-negative microbial agents [15-17]. Various silver
compounds have been used as antimicrobial agents in many healthcare related applications
including; pathogen control, prophylaxis and therapeutic treatments. Salts [18-21], zeolites [2224] and thin film metal coatings [25] have demonstrated some utility as silver ion sources for
medical devices, but concerns regarding cost, performance, bioavalibility, thermal and chemical
stability, and safety have limited the broader adoption of these delivery vehicles in indwelling
device applications. SNP provides a thermally, chemically and photostable reservoir of metal
atoms that are uniquely suited to polymer composite formation while remaining available for
conversion to the active ionic compound upon exposure to physiological solutions. It show
efficient antimicrobial property compared to other salts due to their extremely large surface area,
which leads to better contact with microorganisms [26].
Recent advances in materials development have created silver in nano-form by various
synthesis methods including different reduction methods [27-30], sol-gel process [31-35], CVS
[36-39], CVD and biological approaches [40-51] but none comply the design requirements of
being a robust, high purity, high yield synthesis that results in a chemically stable product being
broadly compatible with bioresorbable/biocompatible thin film coatings.
This study describes a SNP synthesis and purification method producing high purity,
biocompatible, nanomaterial powders and colloidal solutions with tunable chemical properties
and evaluates the applicability of a silver nanomaterial based antimicrobial compound a s a
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chemo-prophylactic agent in bioresorbable/biocompatible thin film coatings. We have
determined the concentrations and contact times required for in vitro elimination of known titers
of two model organisms, Staphylococcus aureus and Escherichia coli. Silver release rate and
nanoparticle erosion as a function of particle concentration and thin film composition is
characterized, along with bioresorbable films response to exposure to simulated physiological
solution. The values obtained provide a baseline for in vivo cytotoxicity studies and is used to
assess how silver nanoparticles can best be implemented in antimicrobial coatings for chronic
indwelling devices.
2.2 Experimental Setup

Figure 2.1. Flow-chart of making SNP based PLLA composite coatings
The overall process of synthesizing and characterizing antimicrobial silver nanomaterials
is divided into four main parts; SNP synthesis, PLLA thin film coatings synthesis, determination
of antimicrobial activity and evaluation of cytotoxicity (Fig. 2.1).
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Our choice of SNP synthesis method is related to the design requirements for chronic
indwelling medical device coatings. Based on design requirements we have selected one of the
chemical reduction methods using formaldehyde as a reducing agent, in an alkaline NaOH
solution to reduce AgNO3 . This is a cost-effective and industry applicable reduction that occurs
at room temperature. The addition of hydroxypropyl cellulose (HPC), a hydrophilic polymer
derived from biomass, acts as a template, [52] stabilizes the particle and provides a mechanism
for concentration and purification. HPC is a thermo-responsive compound and flocculates at
elevated temperatures which facilitate synthesizing concentrated, highly pure and polymer
compatible SNPs with increased permeability [53]. The thermally mediated flocculation and
concentration step allows the bulk residual reaction by-products to be removed by serial
pelleting, washing and resuspension. The synthesized SNP are characterized using widely used
tools such as AFM [54-56], TEM [19, 57] and UV-Visible Spectroscopy to study the presence,
morphology and size distribution of the particles. Other characterization tools including SEM
and DLS are not used as the presence of HPC will introduce artifacts resulting in spurious
morphological descriptions.
In the second step we synthesize thin films coatings comprised of PLLA. A variety of
“natural” (occurring in nature) and synthetic materials have been identified or developed which
broadly meet the criteria to be considered bioresorbable or bioerodible. Some of the broad
categories include aliphatic esters, chitosan, aliginates, polyhydroxy acids and poly(tyrosinecarbonates [58]. PLLA was chosen for this study as in-vivo degradation processes has been well
described and while there are some reports of the onset of late stage inflammation responses,
these have been attributed to high molecular weight particles released from highly crystalline
substrates [59-60]. Most studies have found the implants with PLLA, PLGA or copolymers to
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result in very few rejections related complications [61-62]. The PLLA coatings were engineered
to optimize thickness, substrate adhesion and concentration of the polymer to maximize the
release of SNP. Adhesion testing of the PLLA coatings is also conducted to study their
attachment to the glass surfaces in the presence and absence of APTS linker.
The third process step focused on evaluating the antimicrobial efficacy of the
nanocomposite coatings against the gram positive and gram negative bacteria; Escherichia coli
and Staphylococcus aureus. The concentrations of SNP in the PLLA coatings were optimized to
achieve four log reduction of viable CFU’s for each challenge organism. The ISO 22196
standard protocol is chosen to increase the regulatory relevance of the testing and allow
convenient comparisons to previously published results. The release of SNP from specimens to
the bacterial solution is profiled by TGA and ICP-OES that quantifies the amount of released
SNP in the polymer, and solution respectively
The last step in the experimental design involves varying the antimicrobial
concentration of SNP in the PLLA coatings to quantify the cytotoxicity of the particles against
HeLa cells. In the viability assay, HeLa are stained using Sytox Green and the results, from flow
cytometer, presents the percentage of viable cells against the finalized, working and
recommended concentration of SNP for the coatings.
2.3 Experimental Approach
2.3.1 Reagents
Silver nitrate >99%, Hydroxypropyl cellulose (HPC) with an average molecular weight
of 80,000, Sodium hydroxide (NaOH) at 98%, Formaldehyde 36.5-38%, Antifoam A
concentrate, PLLA with average molecular weight of 100,000-150,000, 2-butanone HPLC grade
≥99.7%, Brain Heart Infusion Agar (BHI), Nutrient Agar, Technical Agar, methanol, sodium
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chloride, sodium phosphate, glutaraldehyde, sodium cacodylate, glycine, uranyl acetate and
osmium tetroxide were purchased from Sigma Aldrich (Sigma Chemical Co, St Louis, MO) and
used without further purification. Dulbecco’s Modified Eagle’s Medium-reduced serum
(DMEM-RS), Dulbecco's Phosphate-Buffered Saline (D-PBS) with Ca2+ and Mg2+, Dulbecco's
Phosphate-Buffered Saline (D-PBS) without Ca2+ and Mg2+ and Trypsin 0.25% were purchased
from HyClone Laboratories, Inc. (Logan, UT). Opti-MEM Reduced-Serum Medium, CalceinAM and SYTOX Green were purchased from Invitrogen (Carlsbad, CA). Ethanol was purchased
from Pharmco-Aaper and Commercial Alcohols (Brookfield, CT). 3-Aminopropyltriethoxysilane
linker was purchased from Gelest, Inc. (Morrisville, PA) and 3% hydrogen peroxide (H 2O 2) was
purchased from Humco (Texarkana, TX). All solvents purchased were of analytical grade.
2.3.2 Methods
2.3.2.1 Microbiology Test Organisms
Escherichia coli (ATCC 29522) and Staphylococcus aureus (ATCC 6538) are inoculated
and grown in sterile 15-ml centrifuge tubes (BD Falcon, Franklin Lakes, NJ) containing Nutrient
Agar and BHI broth respectively and incubated at 37ºC.
2.3.2.2 Cell Culture
HeLa cell (American Type Culture Collection) are maintained in 25-cm2 flasks (BD
Falcon, Franklin Lakes, NJ) with 5ml of Dulbecco’s Modified Eagle’s Medium-reduced serum
(DMEM-RS) supplemented with 3% Fetal Bovine Serum (FBS) and incubated at 37ºC and 5%
CO2. HeLa cells are plated at a density of 80,000 cells/cm2 in 12-well Tissue Culture plates
(Falcon, Franklin Lakes, NJ) for active/direct exposure of SNP. For exposures to PLLA thin
films, cells are plated with a 1 ml 2.6x10 6 cell/ml cell solution in clear glass 60x15-mm glass
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petri dishes (VWR International, LLC, West Chester, PA). Cells were allowed to adhere and
grow for 24 hours prior to every exposure to SNP.

2.3.2.3 Biomass Mediated SNP Synthesis
35 ml of both 125 mM AgNO 3 and 61.5 mM formaldehyde (HCOH) are added, by
syringe pumps (KD Scientific 200,Holliston MA) to a pre dissolved solution containing 0.5 g
NaOH, 0.3125 g HPC, 330 ml DI and 5ul antifoaming agent in RT. This results in the synthesis
of 25-75 nm SNP. Purification is accomplished by thermal flocculation of the solution and
removal of supernatant. The SNP-HPC solution is heated to 70-75oC under static conditions
resulting in flocculation and precipitation. After precipitation the supernatant is removed and the
pellet is resuspended in RT water. This process is repeated 4 times and the resulting pellet dried
and ground yielding a ~98% pure SNP powder (Fig. 2.2). Samples are taken when 10 ml, 20 ml,
30 ml and 35 ml of reactants have been added by syringe pumps to study the time-evolution of
SNP over time by Genesys6 (Thermo Scientific, Madison WI) UV-Visible Spectrophotometer.

Figure 2.2. Process flow diagram of the biomass mediated reduction and purification
process.
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2.3.2.4 Characterization of SNP
For TEM characterization, 5 ul of 800 ppm SNP solution was pipetted on Carbon/Copper
20-30 nm grids (EMS, Hatfield, PA), air dried and visualized with JEOL 100CX.
The AFM analysis was conducted on Agilent 5500, 10 ul of 800ppm SNP solution was
placed on freshly cleaved circular (1×1 cm2) pieces of mica (0001) (Ruby muscovite mica, S&J
Trading Inc., Glen Oaks, NY).
2.3.2.5 PLLA Thin Film Coatings
A 1% PLLA polymer in butanone solution (RED = 0.44-0.48) is stirred for ½ hr at 7580°C until dissolved. The solution is cooled to RT with continuous stirring until the solution
clouds. The butanone volume is maintained to keep the polymer stable. 100 ul of methanol
containing varying concentrations of colloidal SNP is then added to 10 ml of PLLA polymer
solution to create a dilution ladder. Cylindrical glass petri dishes, 60 mm in diameter and 25 mm
in height, are treated with 2% γ-aminopropyltriethoxysilane (APTS) coupling agent for 4-5
minutes and excess solution is removed from the substrate. The substrates are then cured at
100oC for 2-3 mins. 10 mL of SNP containing PLLA solution is poured into the treated dish and
solvent is allowed to evaporate for 24 hrs at RT in a fume hood. After evaporation the substrates
with dried coatings are then extracted in DI water for 24 hrs with DI exchanges every 12 hrs,
followed by incubation at 50°C for 24 hours to extract residual solvent. The coated substrates are
sterilized by autoclaving before antimicrobial and cytotoxicity experiments.
Two PLLA coatings with SNP concentrations of 700 ppm and 5000 ppm along with two
controls, coatings with No SNP and No SNP with 100 ul of HPC, were characterized with
Cambridge Stereoscan 260 SEM (Cambridge Scientific Instruments, Cambridge, UK) at 25 kV
to study the thickness, surface characteristics of the coatings. Each sample is mounted on
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aluminum stubs with either Tubecote or colloidal graphite and sputter coated with a goldpalladium film in an Edwards S-150 sputter coater (Edwards High Vacuum Co. International,
Wilmington, Massachusetts, USA) to image the surface morphology.
Also, TGA was used to quantify the amount of SNP in the polymer. For TGA analysis,
PLLA samples with varying concentrations of SNP (600 ppm-5000 ppm) are cast on glass Petri
dishes (as above) and then samples of PLLA films are analyzed with a TGA 2950 (TA
Instruments New Castle, Delaware) by heating them from RT to a final temperature of 400 oC at
a rate of 15 oC/min.
2.3.2.6 Antimicrobial Activity
Prior to testing, methanol was extracted from the dried coating by soaking in DI water for
24 hrs while exchanging DI water every 12 hrs. This was followed by incubation at 50 °C, in
air for 24 hours to extract residual solvent. The coated substrates are sterilized by autoclaving
before antimicrobial and cytotoxicity experiments.
The quantitative antimicrobial testing on Staphylococcus aureus and Escherichia coli was
conducted according to the ISO 22196 test methods. Briefly, 300 ul of the inoculated bacterial
cultures were exposed to either duplet or triplet coatings for every SNP concentration for 24 hrs.
A coating without SNP was also included in the dilution ladder as a control for each test
organism to measure the efficacy of the coatings.
The antimicrobial activity was calculated using the following equation:
R = (U t − U0) − (At − U0) = Ut − At
R
U0

where;

is the antibacterial activity;
is the average of the common logarithm of the number of viable bacteria, in cells/cm 2,
recovered from the untreated test specimens immediately after inoculation;
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Ut

is the average of the common logarithm of the number of viable bacteria, in cells/cm 2,
recovered from the untreated test specimens after 24 hr;

At

is the average of the common logarithm of the number of viable bacteria, in cells/cm 2,

recovered from the treated test specimens after 24 hr.
2.3.2.7 Silver Release from PLLA Coating
To determine the silver release profile, TGA and ICP-OES are used to study the release
of SNP to determine the mass of silver released upon exposure to PBS. A coating containing 700
ppm SNP was exposed to 7ml PBS solution for 7 days. 4-5 mg polymer samples were collected
with sterile forceps and 1 ml PBS solution was collected everyday for TGA and ICP-OES
analysis respectively. A no-SNP containing control sample was also run to compare the results
obtained.
For TGA, the PLLA samples were analyzed with TGA 2950 (TA Instruments New
Castle, Delaware) by heating them from RT to a final temperature of 400 oC at a rate of 15
o

C/min. For ICP-OES, the released SNP in 1 ml PBS solution was digested with 1 ml nitric acid

and diluted to a final volume of 10 ml with acidified water.
2.3.2.8 Cytotoxicity Experiments/Direct Exposure
HeLa cell are passaged (Appendix A.1.b) and 600 ul cell solution, 80,000 cells/cm2 , is
added to 12-well Tissue Culture plates and incubated for 24 hrs at 37ºC with 5% CO 2. 2 ul of
varying concentrations of SNP (100 ppm-1 ppb), silver nitrate (100 uM-0.1 nM), dissolved in
both DMEM and OPT-MEM, and 2 ul of H2O 2, positive control, are added to 600 ul cell solution
in each well for the next 24 hrs. After 24 hr exposure, the cell solution and sample are aspirated
and 600 ul of D-PBS (with Ca2+ and Mg2+) is added along with 2 ul of 10 nM SYTOX Green for
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5 mins. The stain and DPBS solution is then aspirated and the cells are washed with 400 ul
DPBS. The wells are then imaged using Nikon FL microscope.
2.3.2.9 Electron Microscopy Analysis of SNP Exposed HeLa
The HeLa cells are exposed to 100 ppm SNP and visualized by TEM to study the
mechanism of SNP uptake by the cells. HeLa cells were maintained by serial passaging
(Appendix A.1.b). For testing 600 ul cell solution of 2.6x10 6 cell/ml is added to 12-well Tissue
Culture plates and incubated for 24 hrs at 37ºC with 5% CO 2. 2 ul of 100 ppm SNP concentration
solution, cytotoxic threshold concentration for direct exposure, section 2.4.5, is added to 600 ul
cell solution for the next 2 hrs. 600 ul of Trypsin is added for 10 min to detach the cells from the
wells, followed by addition of 1 ml of DMEM. The 1.2 ml detached cells solution was then
centrifuged at 1800 rpm for 5 minutes and suspended in 1 ml of D-PBS.
The 1ml of cell suspension was aspirated into a syringe containing an equal volume of
4% glutaraldehyde in 0.1M sodium cacodylate buffer, pH 7.2. The fluid was then diluted with 6
ml of 2% glutaraldehyde in 0.1M buffer and drawn into a 10 ml syringe with a Swinney filter
holder (Millipore Corporation, Billerica, MA) fitted with a 13 mm diameter 8 um pore
polycarbonate filter. The filtered cell solution was fixed for 4 hours. The solution was then
washed 4 times in 0.1 M cacodylate buffer containing 0.02 M glycine, post-fixed in 2% osmium
tetroxide for 1 hr, rinsed in water, and bloc stained in 0.5% uranyl acetate in the dark for 1 hr,
rinsed in water and dehydrated in ethanol series. The filter paper was removed from the syringe,
infiltrated in 1:1 ethanol:LR White resin (Electron Microscopy sciences, Hatfielf, PA) solution
for 1 hr, infiltrated in pure LR White for 1 hr, and embedded in LR White overnight at 60 oC.
80-90 nm ultra-thin sections were cut on Ultracut E microtome (Reichert-Jung, Austria) for TEM
analysis. The TEM sections were mounted on coated copper grids (Electron Microscopy
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sciences, Hatfield, PA), stained with Reynolds lead citrate, and examined in a JEOL 100CX
transmission electron microscope operated at 80 kV.
2.3.2.10 Cytotoxicity Experiments on PLLA Films
The HeLa cells are passaged (Appendix A.1.b) using sterile protocols and 1 ml confluent
cell solution, 2x106 cell/ml, is added to the 1% wt PLLA thin films of varying concentration of
SNP (700 ppm-5000ppm) and incubated for 24 hr at 37ºC with 5% CO2. After the 24 hr
exposure, the detached cells are aspirated and 1ml of D-PBS (with Ca2+ and Mg2+) is added to
the petri dishes. The cells are harvested from the coatings by adding 1 ml of Trypsin for 10 min
followed by addition of 1 ml of DMEM. The 4 ml detached and attached cells are pooled and
centrifuged at 1800 rpm for 5 minutes. The solution is aspirated and the cell pallet is resuspended in 1 ml D-PBS and stained by adding 5 ul of 500 uM Sytox Green for 15 mins. The
cell solution is centrifuged again at 1800 rpm for 5 minutes and fixed in 250 ul of 1%
paraformaldehyde (PFA) solution (Appendix A.2.b). The experiment also included negative and
positive controls. A 600 ul cell solution is incubated in 12-well plate for 24 hrs. After the 24 hr,
2 ul of H2O2 is added to the well for positive control for further 24 hrs. After the 24 hr exposure,
the detached cells are aspirated and 600 ul of D-PBS (with Ca2+ and Mg2+) is added to the wells.
The cells are harvested from the wells by adding 600 ul of Trypsin for 10 min followed by
addition of 600 ul of DMEM. The 2400 ul detached and attached cells are pooled and
centrifuged at 1800 rpm for 5 minutes. The solution is aspirated and the cell pallet is resuspended in 1 ml D-PBS and stained by adding 5 ul of 500 uM Sytox Green for 15 mins. The
cell solution is centrifuged again at 1800 rpm for 5 minutes and fixed in 250 ul of 1%
paraformaldehyde (PFA) solution (Appendix A.2.a).
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The viability of fluorescently labeled cells is quantified by BD FACSCalibur cytometer
(Franklin Lakes, NJ).
2.3.2.11 Adhesion Testing
The SiO x substrates were modified with a self assembling monolayer (APTS) to improve
adhesion (as above). The 3-Aminopropyltriethoxysilane (APTS) (Fig. 2.3(a)) acts as an
intermediate linker that forms a discreet monolayer on SiO x and presents an amino group for
interacting with the carbonyl (C=O) groups of PLLA (Fig 2.3(c)). Coatings with and without
APTS linker are tested to quantify the adhesion of the coatings on the glass surfaces.

The tensile strength test is a rapid and reliable method for evaluating the practical
adhesion of thin film coatings on substrates. Double-sided 3M™ 4026 tape (St. Paul, MN) is
applied to the coatings cast on the glass surfaces, and pulled with Instron 8841(Norwood, MA)
at a speed of 2 mm/sec for 20 mm, while the holder, with glass petri dish coated with PLLA
nanocompsoite, is held immobile (Fig. 2.4(a)). The Instron applies tensile force to the coating
and the force cell records the force needed to separate the coating at the coating- glass interface
(Fig. 2.4 a, b and c) . The adhesive links the coating and the metal pull-arm which is linked to the
Instron force cell with Poly (methyl methacrylate) (PMMA) (Fig. 2.4 a and c). The test was
conducted on PLLA coatings attached to the glass surface with and without the APTS linker to
quantify the impact of the APTS linker on adhesion strength. A no-coating control sample was
also analyzed to compare the results obtained.
2.4 Results and Discussion
2.4.1 Biomass Mediated SNP Synthesis
The time-evolution study was performed during the synthesis process to study the
progression and behavior of synthesized SNP as reactants were added via syrings pump. 1 ml
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samples were collected from the final beaker when 10 ml, 20 ml, 30 ml and 35 ml of the
reactants had been added. These four samples clearly showed the successful progression of the
synthesis reaction which produces concentrated silver particles with distinct color change from
greyish-black 10 ml sample to dark grey 35 ml sample. When the final sample was diluted with
DI water, the solution had a goldenish brown color indicating the prescence of SNP. The three
different characterization tools also confirmed the making of poly dispersed SNP. The Genesys 6
UV-Vis spectrometer was used to evaluate all 4 time-evolution based samples and indicated a
clear silver surface plasmon resonance peak at 415 nm confirming the formation of silver
particles with the reduction of silver nitrate with formaldehyde (Fig 2.5) . It should also be noted
that with the addition of reagents, plasmon resonance peak was not shifted right, as may be
expected with increase in the particle size, while the absorbance value increased from 0 to 2.5.
With this observation, we conclude that using this method we synthesize monodispersded SNP
and with the progression of the process we concentrate the final solution with monodispersed
SNP instead of synthesizing diferent sized SNPs.

Figure 2.3. (a) Molecular structure of 3-Aminopropyltriethoxysilane linker. (b) Detailed
mechanism and chemistry behind linker-substrate bond (c) the overall linking mechanism
of glass surface, APTS linker and the PLLA coatings
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Figure 2.4. (a) General set-up for testing the adhesion of PLLA coatings on the glass
surface. (b) PLLA coating attached to the double-sided tape. (c) Tensile testing on Instron
with PMMA holders securing the coating with metal grips.

Figure 2.5. UV-Vis Spectrum of SNP indicating the time-evolution of the synthesis process.
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The SNP morphology was analyzed by TEM using a JOEL CX100 electron microscope.
Fig 2.6 show the importance and potential function of HPC aside from being used as the
stabilizing agent and thermo-responsive compound. The figure includes 3 images (Fig 2.6 a, b
and c) with increasing magnification. The lighter colored areas of the particles (Fig 2.6 (c)) are
likely HPC, rich regions encapsulating more dense, and darker, silver laden regions. The HPC
molecule acts as the precursor substrate attracting silver nitrate through hydrogen bond [63], and
SNP are formed as formaldehyde reduction takes place. The HPC substrate acts to evenly
disperse the silver nitrate and thus produces more monodispersed and highly concentrated SNPs
compared to other reduction based synthesis methods. This SNP synthesis method produced
metal nanoparticles with a size distribution from 25-75 nm, as determined by TEM.

Figure 2.6. Three TEM images of SNP with increasing magnification (a) 20K (b) 160K
(c) 250K. The scale bar is given with each image.

43

AFM was used to assess the z-directional dimension of the SNPs. The height of SNPs
was measured by samples placed on freshly cleaved circular pieces of pieces of mica (0001) and
a standard soft cantilever with spring constants ranging from 0.05 to 0.1 N/m, was used for
imaging in contact mode. The root mean square (RMS) height of SNP was measured to be 114
nm and is not in agreement with TEM images of the SNPs. (Fig 2.7)

Figure 2.7. AFM images of SNP. The images show that the height of these SNP is around
150 nm when measured with the scale bar
The overall characterization by using spectroscopy and EM based analytical tools
confirmed the synthesis of concentrated, non-agglomerated and biocompatible SNP. The novel
synthesis of encapsulating SNP in a biocompatible cellulose derivative ensured the potential use
of SNP for the reduction of biofilm in chronic indwelling medical devices.
2.4.2 PLLA Thin Film Coatings
2.4.2.1 Characterization of PLLA Film
The PLLA nanocpmposite thin films were cast on glass petri dishes in an effort to
optimize the thickness, substrate adhesion silver release. SEM images of PLLA nanocomposite
demonstrate that the casting process yield uniform thin films approximately 50 um thick (Fig. 2.8
e and f) with a corresponding volume of 9.82 mm3. The composite surface morphology is greatly
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influenced by the HPC content of the coatings. The SNP are stabilized with HPC and the bulky
molecular structure of HPC introduces artifacts in the morphology of the composites. Comparing
the surfaces of 700 ppm with 5000 ppm films (Fig 2.8 c and e) it can be seen that the surface of
later coating is smoother and more homogenous than that of film containing 700 ppm SNP.
Similarly, while comparing the surfaces of PLLA coating without SNP (Fig 2.8 (a)) and a PLLA
coating with HPC (Fig 2.8 (b)), the surface of PLLA coating with HPC is smoother and more
homogenous than that of PLLA coating without HPC. Based on these SEM images, the particle
to volume ratio for 700 ppm and 5000 ppm coatings is 3.98 x 10 16 and 2.84x 1017 SNP particles
per millimeter cube of the film.

Figure 2.8. SEM images of 1% PLLA thin film coatings. (a) Surface of PLLA coating with
No SNP. (b) Surface of PLLA coating with No SNP and 100 ul HPC. (c) Surface of PLLA
coating with 700 ppm SNP. (d) Surface of PLLA coating with 5000 ppm SNP. (e) Crosssection of PLLA coating with 700 ppm SNP (f) Cross-section of PLLA coating with 5000
ppm SNP.
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The TGA results of the amount of SNP present in the coatings are shown in Appendix
B.1. The lower detection limit of TGA 2950 system is higher than the amount of SNP present in
the PLLA coatings and statistically valid readings were not obtained by this characterization
method.
2.4.2.2 Concentration of PLLA Films
The cast coating process for PLLA biocompatible/bioresorbable coatings was optimized
to form thin films with good adhesion and release of silver ion. Solvents for casting had to be
chosen cafefully to reduce potential cytotoxic and antibacterial side effects. Also, the solvent
had to be miscible with the polar solvents used to dissovle powder SNP. Methanol dissolves
HPC stabilized SNP adequetly resulting in a collidal supension of metal particles, additionally
residual ethanol can be easily removed from the cast polymer by DI washes. Many publications
used chloroform [64] as the potential solvent for PLLA but the presence of Cl- could act as
residual antimicrobial agent resulting in false positive results for our applications or conversly
could react with free silver cation forming insoluble chloride salts. Agrawal and etc. lists many
potential solvents of PLLA based on RED values and we selected the methyl ethyl ketone (2 butanone) as the solvent for dissolving PLLA [65]. The solvent has a solubility limitation and
only 1%wt PLLA polymer can be dissolved in butanone. After optimizing the concentration of
PLLA catsing conditions were defined. The differences in thermal expansion coefficients of the
film and the glass petri dishes can cause mechanical stress. By casting and bonding the films on
the glass surface the extrinsic stress was eliminated as they both are constrained in the lateral
direction and the stresses develop equally. This results in uniform and adherent coatings. Fig 2.9
shows the difference between optimized coating (Fig 2.9 (b)) and coatings cracking under tensile
stress conditions. The coating (Fig 2.9 (a)) was casted by filling the maximum amount of
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solution 60 mm x15 mm petri dishes could hold while coating (Fig 2.9 (b)) was casted by
pouring 10 ml of 1% PLLA solution.

Figure 2.9. Difference between two coatings with same polymer concentration (1%) but
different polymer amounts. (a) Coatings buckling due to thin film stress (b) Optimized
coating.
2.4.2.3 Drying Conditions for PLLA Films
Next, the drying conditions were optimized to achieve uniform coatings for its effective
performance. The PLLA cast coatings dry really fast and perfect conditions have to be
maintained to facilitate their drying procedure. The solvent was evaporated under fume hood
and different conditions were evaluated to study the drying process. Fig 2.10 shows the
difference in coatings homogeneity and consistency of the coatings. Coating (Fig 2.10(a)) was
dried at RT with open vent to speed up the drying process which resulted in non-homogeneous
and hard, white low stress coating. On the other hand, drying at RT with negligible air flow
aides in formation of low stress polymer (Fig 2.10 (b)).
2.4.2.4 Treatment of PLLA FiLms
Prior to testing, methanol was extracted from the dried coating by soaking in DI water for
24 hrs while exchanging DI water every 12 hrs. This is followed by incubation at 50 °C, in air
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for 24 hours to extract residual solvent. The coated substrates are sterilized by autoclaving before
antimicrobial and cytotoxicity experiments.

Figure 2.10. Difference between two coatings with same polymer concentration (1%) but
different drying conditions. (a) Coatings “hardening” under the influence of air flow (b)
Optimized coating.
2.4.3 Antimicrobial Activity
After sterilizing the coatings, two microorganism Escherichia coli and
Staphylococcus aureus were tested against varying amounts of SNP embedded in the coatings to
create a dilution ladder. They were chosen as they are the two most commonly occurring strains
of bacteria in Healthcare Acquired Infections (HAI) and both strains have demonstrated resistant
to many antibiotics including amoxicillin and methicillin respectively [66]. A standard
procedure, detailed in the ISO 22196 protocol was followed for microbial challenge assays. The
target was to generate a 3-5 log reduction in the number of viable bacteria. The colony forming
unit (CFU) values of the controls are 2.25x10 7CFU/ml for S.aureus and 5.54 x105 CFU/ml for
E.coli. The percentage bacterial reduction of S.aureus and E.coli for the various experimental
groups can be seen in Fig 2.12. The results indicate S.aureus is more resistant to silver
inactivation when compared E.coli, this may be related to the thick peptidoglycan layer of gram
positive bacteria. At 700 ppm SNP, we obtain a 3 log reduction, 99.9%, for S.aureus (Fig 2.11

48

(a)) and 4 log reduction for E.coli, 99.9% (Fig 2.11 (b)). There is also a clear lower SNP
concentration threshold of ~500 ppb after which the reduction of bacteria is negligible (Fig 2.11).
The percentage bacterial reduction drops from 41.7% to 7.8% for S.aureus (Fig 2.11 (a)) and
50% to 2.58% for E.coli (Fig 2.11 (b)).
Fig 2.12 shows the decrease in bacterial colonies across the SNP concentration and it can
be seen that at 700 ppm the CFU values decrease from 2.25x10 7CFU/ml to 4.10 x10 4 for
S.aureus (Fig 2.12 (a)) and from 5.54 x10 5 CFU/ml to 5.60 x101 for E.coli (Fig 2.12 (b)).
Based on these consistent results we can recommend 700 ppm as the antimicrobial
concentration for the PLLA based SNP containing chronic indwelling medical device thin film
cast coatings.
We also tested the effects of using APTS linker on the antimicrobial activity of the SNP
composite coating against both organisms. For a fixed SNP concentration of 500 ppb, two
coatings are prepared; one with and the other without the APTS linker. There is no apparent
difference in bacteriocidal activity of the two groups (Fig 2.13 and Fig 2.14). The percentage
difference is 0.08 % and 2.7% for S.aureus and E.coli respectively (Fig 2.13 a and b). The initial
CFU values are 2.25x10 7 CFU/ml for S.aureus and 5.54 x105 CFU/ml for E.coli. The bacterial
count remains 1.20x10 7 CFU/ml for S.aureus while it changes from 2.77 x10 5 to 5.08 x105
CFU/ml for E.coli on APTS and non-APTS coatings (Fig 2.14 a and b). These changes in CFU
values for S.aureus and E.coli are statistically insignificant as the p-values, 0.24 and 0.056
respectively, are higher than either 5% or 1% significance level. With minimal and
insignificance difference, it can be concluded that using APTS linker to improve the adherence
of PLLA coatings does not have substantial effect on the viable bacteria and the data collected in
Fig. 2.11 and Fig 2.12 is solely due to the presence of SNP in the coatings.
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Figure 2.11. Graphs representing the percent bacterial reduction when exposed to varying
concentrations of SNP. (a) 4 log reduction of S.aureus (b) 3 log reduction E .coli
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Figure 2.12. Graphs representing the reduction in bacterial colonies when exposed to
varying concentrations of SNP. (a) for S.aureus (b) for E .coli
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.

Figure 2.13. Graphs representing the percent bacterial reduction with the presence and
absence of APTS linker. Both coatings have a fixed SNP concentration of 500 ppb. (a)
Comparison between coatings for S.aureus (b) Comparison between coatings for E .coli.
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Figure 2.14. Graphs representing the reduction in bacterial colonies with the presence and
absence of APTS linker. Both coatings have a fixed SNP concentration of 500 ppb. (a) for
S.aureus (b) for E .coli.
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The extraction of residual solvents from the PLLA coatings proved to be an essential step
to generate reproducible antimicrobial results. The biocidal of these residual solvents is
demonstrated in Fig 2.15 and Fig 2.16. There was a difference of 17.9 % and 8.84% for S.aureus
and E.coli exposed coatings when comparing the pre-treated and post-treated coatings
respectively (Fig 2.15). This difference can be appreciated while comparing the difference is
bacterial counts. The bacterial count decreases from 6.25x10 6 to 2.58x106 CFU/ml for S.aureus
and 1.66 x105 to 1.17 x105 CFU/ml for E.coli on pre-treated and post-treated coatings (Fig 2.16).
It is likely that these residual solvents would also be toxic to mammalian cells.
Based on the results demonstrated in Fig 2.11, Fig 2.12 and Fig 2.13 we concluded that
an antimicrobial concentration of 700 ppm meets the design requirement of reducing the count of
viable bacterial CFU’s by 3-5 log. Also, the addition of APTS improves the adhesion of the
coatings to the surface without impacting antimicrobial efficacy.
(a)

Figure 2.15. Graphs representing the percent bacterial reduction for pre-treated and posttreated coatings. Both coatings have a fixed SNP concentration of 200 ppm. (a) Comparison
between coatings for S.aureus (b) Comparison between coatings for E .coli. (Fig. contd.)

54

(b)

(a)

Figure 2.16. Graphs representing the reduction in bacterial colonies for pre-treated
and post-treated coatings. Both coatings have a fixed SNP concentration of 200 ppm. (a) for
S.aureus (b) for E .coli. (Fig. contd.)
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(b)

2.4.4 Silver Release Profile
The antimicrobial and bacterial reduction performance of these coatings is based on the
efficiency of silver release from the polymer. Determining the rate of silver release with respect
to time and correlating these results with bacteriocidal performance will allow the generation of
design heuristics for the composite coatings Fig. 2.8.
TGA was used to analyze a 700 ppm SNP polymer samples over a period of 6 days to
determine the mass of silver released upon exposure to bacteria. The TGA results of the amount
of SNP present in the coatings are shown in Appendix B.2. The lower detection limit of TGA
2950 system is higher than the amount of SNP present in the PLLA coatings and therefore
statistically valid results were not obtained by this characterization method.
The release of SNP from and ions from the biocompatible/bioresorbable polymer based
coating after being soaked in DPBS is measured by ICPOES and shown in Fig. 2.17. This
analysis enables us to quantify the release of SNP from the coatings in a time-based study. It can
be seen that a total of 506 ppb SNP is released after 7 days. The PLLA coating plays an
important role in controlling the amount of released SNP below the high cytotoxicity threshold
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of 100 ppm (Fig 2.18) making the embedded SNP safe to be used in chronic indwelling medical
device coatings.

Figure 2.17: Release of SNP from the PLLA coatings over a period of 7 days. The release
was measured by ICPOES
2.4.5 Cytotoxicity Experiments/Direct Exposure
Our initial experiments examined the cytotoxic threshold of SNP and silver nitrate when
directly exposed to the cells. HeLa cells, a cervical cancer derived line, were chosen for these
experiments. The HeLa were passaged using sterile protocols and exposed to SNP and silver
nitrate concentrations ladder ranging from 1 ppb to 100 ppm and 0.1 nM to 100 uM
(approximately 0.017 ppb to 17 ppm) respectively. The silver nitrate results were compared to
SNP because it has long history of use for reducing the transmission of infection from mother to
child during birthing. [67]. The study also conducted to compare the cytotoxicity of SNP and
silver nitrate in the presence or absence of serum. The DMEM media contains naturally
occurring proteins closely resembles the in vivo and physiological environments that will
surround the coatings. The cells were stained using SYTOX® Green which penetrates the
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damaged plasma membranes of dead HeLa cells. The cytotoxicity of HeLa in DMEM is given in
Figure 2.18 showing only the upper and lower limits along with positive and negative controls.
(a) Negative control

Figure 2.18. Sytox used to represent their cytotoxicity against SNP and silver nitrate in
DMEM media. The 1 st image is Bright Field, 2 nd image is FITC and 3 rd is the overlay of
first two images.(a)Negative control (Live HeLa) (b) Positive control (H 2O2) (c) 100ppm
SNP (d) 500ppb SNP (e)100ppb SNP (f) 100uM silver nitrate (17ppm) (g) 10nM silver
nitrate (1.7ppm) (h) 1nM silver nitrate (0.017 ppm). The images are at 20x (Fig. contd.)
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These results indicate that for SNP and silver nitrate, 100 ppb and 0.017 ppb are the noncytotoxic threshold values respectively at which they are non-cytotoxic in serum-containing
media. Silver nitrate has a lower cytotoxic threshold than SNP this is probably a result of its high
solubility, low chemical and thermal stability which results in high concentration bolus of the
ionic form.
Experiments conducted in serum free media demonstrated a 100 fold decrease in
cytotoxic thresholds for both SNP and AgNO 3 while relative toxicity remained the same. The
decreased cytotoxicity associated with serum containing environments is likely related to the
chelation of silver ion through non-specific, protein-Ag ion interactions mediated by sulfhydryl
and amine groups. In Fig 2.19 it can be seen that the lower limit of both SNP and silver nitrate
increased from 100ppb to 1ppb and 1nM (0.017 ppb) to 0.1 nM (0.0017 ppb) respectively.
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(a)Negative control

Figure 2.19. Sytox used to represent their cytotoxicity against SNP and silver nitrate in
OPTI-MEM media. The 1st image is Bright Field, 2 nd image is FITC and 3rd is the overlay
of first two images.(a)Negative control (Live HeLa) (b) Positive control (H2O2) (c) 100ppm
SNP (d) 1ppb SNP (e)100uM silver nitrate (e) 0.1nM silver nitrate. The images are at 20x
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This in-vitro cytotoxicity testing, conducted similar physiological environment excepted
during and after implantation allowed predictions to be made regarding the target SNP
concentration required to cause cell death during their passive exposure to SNP.
2.4.6 Electron Microscopy Analysis of SNP Exposed HeLa
TEM imaging was used analyze SNP interaction with the cellular membrane of live HeLa
cells. The cell wall and intracellular structures of control HeLa can be seen in electron
micrographs (Fig. 2.20 a and b) and the interaction of SNP with the cell membrane of treated
cells can be seen in Fig 2.20 c and d. In the cells treated with 100 ppm SNP, cytotoxic threshold
concentration for direct exposure (Section 2.4.5), the early stages of SNP endocytosis can be
seen to be occurring in Fig 2.20 c and d. Additionally, potential sites of membrane compromise
are associated with points where SNP have contacted the cell membrane.

Figure 2.20. TEM images of 80-90 nm sections of HeLa cell when directly exposed to 100
ppm SNP. (a) Live HeLa at a magnification of 3.3K (b) Live HeLa at a magnification of
6.6K (c) Live HeLa exposed with 100 ppm SNP at a magnification of 26K. (d) Live HeLa
exposed with 100 ppm SNP at a magnification of 50K
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2.4.7 Cytotoxicity Experiments on PLLA Films
After finding the effective antimicrobial concentration of SNP, the effects of various
SNP concentrations were tested against HeLa to find the cytotoxicity range of PLLA coatings
to recommend an efficacious and non-cytotoxic SNP concentration for industrial use. The
PLLA coatings were casted as described in section 2.3.2.4 and autoclaved before the
cytotoxicity experiments. The SNP concentration varied from 700 ppm to 5000 ppm (5 ppt)
and the 24 hr exposure time was chosen for comparing results with the antimicrobial activity
experiments.
The results in Fig 2.21 shows that HeLa are very resistant to SNP and have minimal
effect of their viability even when exposed to high 5000 ppm SNP concentration via PLLA
coating barrier. These results when compared with Fig 2.18 and Fig 2.19 show that having a
PLLA thin film coating barrier reduces the effect of SNP on the cells and improve their
biocompatibility in in vivo environments. With direct exposure, 100 ppm SNP proved
cytotoxic to almost all the cells (Fig 2.18 (c)) while 5000 ppm SNP is the cytotoxic
concentration for PLLA coatings with only 25.68% live HeLa cells (Fig 2.21). For the
antimicrobial SNP concentration of 700 ppm 81.34% of HeLa cells are healthy and this
concentration is both efficacious to microbes and non-cytotoxic to cells.
Figure 2.22 is a good representation of the results shown in Fig 2.21. The Forward
Scatter (FSC) vs. Side Scatter (SSC) enabled us to look at the distribution of cells based upon
size. As the Argon laser passed through the stream, light was deflected and refracted by the cells
in the stream. Fig 2.22 (a) shows a typical closely tight and homogenous scatter plot of live cells
while the scatter plot of Fig 2.22 (b) is shifted upward picking up the internal granularity and
complexity in the cell debris of the dead HeLa cells. The R2 region is gated to include all the live
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HeLa cell population while the M1 marker represents the percentage of dead cells. Also while
comparing the positive and negative controls the clump outside the R1 regions grows in Fig 2.22
(b) comparatively, indicating a good dead control sample. The percentage values of viable HeLa
cells shown in Fig 2.21 are obtained from the M1 marker that distinguishes the dead and live cell
region based on the intensity of Sytox Green signals collected at the PMT tubes. The Sytox
Green vs. Counts graph is a comparative analysis in which the higher fluorophore signals
represent a sample with compromised membrane while the lower fluorophore signals represent a
sample with healthy cell membrane.
The Fig 2.22 (c, d and e) are of No SNP, 700 ppm and 5000 ppm (5 ppt) SNP
concentration respectively and based on M1 marker and R2 region gate, drawn on the basis of
controls; all three proves the non-cytotoxicity and biocompatibility of SNP and PLLA films to
HeLa cells.

Figure 2.21. Graphs representing the reduction of HeLa when exposed to varying SNP
concentrations. It also includes positive and negative controls to better comparison and
functioning of the Sytox Green fluorophore
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Figure 2.22. The results obtained from flow cytometer. The first image is a Forward vs.
Side scatter and the second image is the intensity of Sytox Green picked on the PMT tubes.
(a) Negative control (Live HeLa with Sytox Green) (b) Positive control (dead HeLa with
Sytox Green). (c)NO SNP (d) 700 ppm SNP (e) 5000 ppm SNP.
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2.4.8 Adhesion Testing
Strong adhesion of nanocomposite coatings is critical for the use in dwelling
applications as delamination cracking could result in inflammation, immune response and/or
tissue damage. The adhesion of the PLLA coatings in this study was greatly improved by
addition of a self-assembling monolayer (SAM) of APTS linker (Fig 2.23). PLLA coatings cast
without APTS SAM fails the standard scotch tape test and the tensile adhesion strength for this
coating is assumed as 0 MPa. For the glass control, without PLLA coatings, the adhesion
strength was measured to be 115.66 MPa, the force required to delaminate the double-sided tape
from the bottom glass surface of a petri dish. The force required to induce delamination of the
final engineered SNP PLLA composite coatings with addition of the SAM was measured as
282.44 MPa (Fig 2.23). These results from sections 2.4.3 and 2.4.8 indicate the APTS SAM
substantially improves the adhesion of PLLA coating to the oxide surfaces without negatively
affecting the antimicrobial performance.

Figure 2.23. Tensile strength of PLLA coating when attached to the surface with and
without the APTS linker.

65

2.5 Conclusions
In this study we demonstrated a novel, cost effective and, concentration and biomass
mediated method of synthesizing silver nanomaterial powders and colloidal solutions with
tunable chemical properties. The resulting SNP are biocompatible, non-agglomerated,
polydispersed, industrially relevant and of high purity. The 25-75 nm sized SNP are synthesized
to be used in the chronic devices coatings as antimicrobial agents. The biocompatible/
bioresorbale PLLA based coatings are embedded with the SNP and it helps reduce the E.coli and
S.aureus bacterial colonies by 99.9-99.99%. Based on the cytotoxicty and antimicrobial activity
experiments we recommend a safe antimicrobial concentration of 700 ppm for these coatings
that is both efficacious to the microbes (99.9-99.99% reduction) and non-cytotoxic (81.34% live
HeLa) to the surrounding cells. Also, increasing the SNP concentration beyond 700 ppm will
only have economic and aesthetic constrains as higher concentration does not have any better
antimicrobial or cytotoxic results. The APTS adhesion linker increases the likeliness of these
coatings to be used in actual chronic indwelling devices to help reduce the surgical site and
Healthcare Acquired Infections (HAI) that immensely burdens the healthcare providers for
services provided related to treating healthcare associated conditions. Clearly, further work is
needed to conduct in vivo testing for chronic devices with SNP-containing PLLA coatings to
study the antimicrobial and cytotoxicity results simultaneously.
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CHAPTER 3. ANTIMICROBIAL BIOCOMPATIBLE BIOSCAFFOLDS
FOR TISSUE REGROWTH
3.1 Introduction
With ever growing donor list and, an increasing rates of infection and foreign body
reactions, advancements in the field of biomaterial tissue engineering are vital to safe and
successful repair of damaged tissues [1]. The shortage of tissues and organs for transplant
medicine is on the rise across the globe. Nationally, nearly 1 million patients suffer from burn,
1.25 million patients from pressure sores, 1.5 million patients from ailments requiring bone
grafts, hip and other joint replacements and millions of patients from the loss of teeth and dental
tissues. These alarmingly high numbers of patients will benefit from an engineered tissue
solution which improves healing outcomes [1].
Increasingly tissue engineering research is being explored as a potential therapeutic
modality to address limitations of tissue grafting and alloplastic tissue repair. The objective is to
deliver bioactive materials such as cells, genes, drugs, peptides and/or proteins concomitantly
with a degradable scaffold. The concept has grown to encompass stem-cell and gene-therapy
approaches, with an objective of stimulating tissue repair or tissue replacement. The materials
and porous architecture common in most scaffold designs perform a critical function in tissue
regeneration by maintaining tissue volume, providing temporary mechanical stability, and
delivering bioactive compounds (2-7).
For nearly 40 years research in the field of biocompatible materials has been directed to
the development and characterization of “bioerodible” or “bioresorbable” materials.(8)

These

materials, which can be degraded and excreted from the body over an extended period of time,
ranging from days to years, have found use in a variety of applications including sutures, tissue
scaffolds and drug eluting devices. (9)
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A variety of “natural” (occurring in nature) and synthetic materials have been identified
or developed which broadly meet the criteria to be considered bioresorbable or bioerodible.
Some of the broad categories include aliphatic esters, chitosan, aliginates, polyhydroxy acids and
poly(tyrosine-carbonates). (10) Of these compounds the material and chemical properties of
aliphatic esters such as poly-L-lactic acid (PLLA) and poly-L-glycolic acid (PLGA), make them
of interest for many indwelling applications including wound care and orthopedic device
applications. The in-vivo degradation processes of these compounds have been well described
and while there are some reports of the onset of late stage inflammation responses, these have
been attributed to high molecular weight particles released from highly crystalline substrates.
(11, 12) Most studies have found the implants with PLLA, PLGA or copolymers to result in
very few rejection related complications. (13, 14)
Many publications have described the use fibrous scaffolds as a delivery vehicle for
antimicrobial agents to treat number of infections such as periodontitis, osteomyelitis,
tuberculosis and brucellosis (17-22). The PLLA based biocompatible bioscaffolds release
encapsulated drugs in a predictable manner, related to the physico-chemical properties of the
polymer and drug. Nanocomposite compounds provide a novel and flexible platform for
incorporating drugs and other bioactive components into scaffolds. The large surface area and
higher reactivity of nanoparticles when compared to bulk solids allow the particles to exhibit
extraordinary chemical, physical and biological properties while the fundamentally small size
minimizes the deleterious impacts traditionally associated with the formation of polymer
composites containing a high volume fraction of solids.(23)
This chapter evaluates the use of SNP nanocomposite PLLA-PEG co-block polymer
bioscaffolds as a potential antimicrobial drug delivery system. We will determine the
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concentrations and contact times required for the elimination, in vitro, of known titers of two
model organisms, Staphylococcus aureus and Escherichia coli. The values obtained will provide
baseline data to assess how SNP can best be implemented in nanocomposite bioscaffolds to
create engineered, active antimicrobial tissue scaffolds.
3.2 Experimental Approach
3.2.1 Reagents
Silver nitrate >99%, Hydroxypropyl cellulose (HPC) with an average molecular weight
of 80,000, Sodium hydroxide (NaOH) at 98%, Formaldehyde 36.5-38%, Antifoam A
concentrate, PLLA with average molecular weight of 100,000-150,000, Poly(ethylene glycol)
with a relative molecular mass of 1900-2200, 1,4-Dioxane, 99.8%, Brain Heart Infusion Agar
(BHI), Nutrient Agar, Technical Agar, sodium chloride and sodium phosphate were purchased
from Sigma Aldrich (Sigma Chemical Co, St Louis, MO) and used without further purification.
Ethanol was purchased from Pharmco-Aaper and Commercial Alcohols (Brookfield, CT). All
solvents purchased were of analytical grade.
3.2.2 Methods
3.2.2.1 Microbiology Test Organisms
Escherichia coli (ATCC 29522) and Staphylococcus aureus (ATCC 6538) are inoculated
and grown in sterile 15-ml centrifuge tubes (BD Falcon, Franklin Lakes, NJ) containing Nutrient
Agar and BHI broth respectively and incubated at 37ºC.
3.2.2.2 Biomass Mediated SNP Synthesis
35 ml of both 125 mM AgNO 3 and 61.5 mM formaldehyde (HCOH) are added, by
syringe pumps (KD Scientific 200,Holliston MA) to a solution containing 0.5 g NaOH, 0.3125 g
HPC, 330 ml DI and 5ul antifoaming agent at RT. This synthesis results in particles with a size
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distribution ranging from 25-75 nm SNP, as determined by TEM. Purification is accomplished
by thermal flocculation of the solution and removal of supernatant. The SNP-HPC solution is
heated to 70-75oC under static conditions resulting in flocculation and precipitation. After
precipitation the supernatant is removed and the pellet is resuspended in RT water. This process
is repeated 4 times and the resulting pellet dried and ground yielding a ~98% pure SNP powder
(Fig. 3.1). 1ml samples were taken when 10ml, 20ml, 30ml and 35ml of reactants have been
added by syringe pumps to study the time/concentration-evolution of SNP. These samples were
characterized using Genesys6 (Thermo Scientific, Madison WI) UV-Visible Spectrophotometer.

Figure 3.1. Process flow diagram of the biomass mediated reduction and purification
process.
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3.2.2.3 Characterization of SNP
For TEM characterization, 5 ul of 800 ppm SNP solution was pipetted on Carbon/Copper
20-30 nm grids (EMS, Hatfield, PA), air dried and visualized with JEOL 100CX.
The AFM analysis was conducted on Agilent 5500, 10 ul of 800ppm SNP solution was
placed on freshly cleaved circular (1×1 cm2) pieces of mica (0001) (Ruby muscovite mica, S&J
Trading Inc., Glen Oaks, NY).
3.2.2.4 Synthesis of Porous Bioscaffolds
The 7% PLLA and PEG (50:50 by wt) are codissolved in dehydrated 1, 4-dioxane at
50oC until transparent. Then 280 ul of DI water containing varying concentrations of colloidal
SNP (800 ppm-500 ppb) are mixed into the PLLA/PEG solution. After cooling to RT, the
solution is poured into a closed 4 cm long glass vial. The material is then frozen uni-directionally
by immersing the test tube into a liquid nitrogen bath at a constant rate of 2.0 cm/hr. The cap is
closed to prevent absorption of moisture. After freezing, the solidified sample is freeze-dried in
Labconco FreeZone Plus (Kansas City, MO) at -5oC for 4 days. The honeycomb monolith
structures are then soaked in ethanol for 3 days and the ethanol is replaced every 12 hr to ensure
complete extraction of the PEG. After PEG extraction, the samples are again freeze-dried at -5oC
to remove residual ethanol.
3.2.2.5 Characterization of Monolith Bioscaffolds
The solidified 4 cm long monolithic porous bioscaffolds were characterized with
Cambridge Stereoscan 260 SEM (Cambridge Scientific Instruments, Cambridge, UK) at 25 kV.
The top half of the bioscaffold is cut with a sharp razor blade both parallel and perpendicular to
the direction of freezing to get hemi-cylindrical shaped samples. These samples were mounted
on aluminum stubs with either Tubecote or colloidal graphite and sputter coated with gold-
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palladium in a Edwards S-150 sputter coater (Edwards High Vacuum Co. International,
Wilmington, Massachusetts, USA) to better study the surface morphology of the bioscaffolds.
3.2.2.6 Antimicrobial Activity
The quantitative antimicrobial testing on Staphylococcus aureus and Escherichia coli is
conducted according to the ISO 22196 test methods with few modifications. The bioscaffold is
cut with a sharp razor blade both parallel and perpendicular to the direction of freezing to get
hemi-cylindrical shaped samples. Scaffolds with varying SNP concentration were then
inoculated with 300 ul of 2.3 x 108 CFU/ml Staphylococcus aureus and Escherichia coli cultures
for 24 hrs. The SNP concentrations examined ranged from 10 ppb-800 ppm and also included a
control bioscaffold without SNP. The bacterial count is quantified by extracting the scaffolds
with 1 ml PBS and plating serial dilutions of the bacterial solution on Nutrient Agar or BHI
plates.
Based on the bacterial colony values obtained from plates, he antimicrobial activity can
be calculated using the following equation:
R = (U t − U0) − (At − U0) = Ut − At
R
U0

where;

is the antibacterial activity;
is the average of the common logarithm of the number of viable bacteria, in cells/cm 2,
recovered from the untreated test specimens immediately after inoculation;

Ut

is the average of the common logarithm of the number of viable bacteria, in cells/cm 2,
recovered from the untreated test specimens after 24 hr;

At

is the average of the common logarithm of the number of viable bacteria, in cells/cm 2,

recovered from the treated test specimens after 24 hr.
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3.3 Results and Discussion
3.3.1 Characterization of Monolith Bioscaffolds
Figure 3.2 (a and b) shows a pair of SEM micrographs of a PLLA/PEG 50:50 blend after
unidirectional freezing and freeze-drying. This cross-sectional view of the sample parallel to the
direction of freezing provides an image of the honeycomb monolith structure, which has porous
20 um microtubes aligned along the freezing direction.

Figure 3.2. SEM images of PLLA/SNP monolith bioscaffolds. The samples are coated with
gold-palladium and the surface morphology is studied under SEM. The microtubules are
parallel and are 20 um wide. (a) SEM image at 86.1K (b) 20um wide channels shown at
268K magnification.
3.3.2 Antimicrobial Activity of SNP in Bioscafffolds
The bioscaffold nanocomposite compounds were challenged with two microorganisms
Escherichia coli and Staphylococcus aureus. . These strains were chosen as they are the two
most commonly occurring strains of bacteria in Healthcare Acquired Infections (HAI) and have
demonstrated resistance to several antibiotics including amoxicillin and methicillin respectively
[17]. The dilution ladder of SNP composites was comparable to samples synthesized and
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characterized in chapter 2. A bioscaffold without SNP was also included in the dilution ladder as
a control for each test organism to measure the efficacy of the bioscaffolds.
Fig 3.3 shows the percentage bacterial reduction across varying SNP concentration for
S.aureus and E.coli on the top half of monolithic bioscaffold. It can be seen in Figure 3.3 that at
every SNP concentration the reduction in viable S.aureus compared that of E.coli. The thick
peptidoglycan layer of S.aureus is believed to be interacting with the silver ions reducing the
cytotoxic activity compared to E.coli. At 800 ppm SNP, we obtain a 92.8% reduction for
S.aureus (Fig 3.3 (a)) and 3 log (99.9%) reduction for E.coli (Fig 3.3 (b)).
The antimicrobial activity varies with position along the axis of freezing within the
structure. No significant bacterial reduction occurs while challenging the lower portion of
monolithic bioscaffold samples. The SEM images show that the 20 um microtubes are more
oriented tubular in the top half of the scaffold, compared to dendritic structure common in the
lower portion of the structure. We hypothesize that the SNPs are excluded from the structure
during precipitation in the bottom portion of the monolith and to the conditions which promote
the more regular crystalline structure in the upper regions promote inclusion of the SNP.
While comparing these results to the cast materials reported on in chapter 2, these
antimicrobial bioscaffolds have a different efficacy ladder. The cast PLLA coatings demonstrate
a 3-4 log reduction at 700 ppm (Fig 2.12 a and b) while the unidirectionally precipitated
scaffolds decrease the bacterial colonies by 92.5% and 99.9% at a higher concentration of 800
ppm (Fig 3.3 a and b). Also, the lower antimicrobial threshold for the cast PLLA coatings is
~500 ppb (Fig 2.12 a and b) while at this concentration the bioscaffolds are still efficacious,
reducing the bacterial colonies of S.aureus and E.coli by 71.4% and 25% (Fig 3.3 a and b).
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Figure 3.3. Graphs representing the percent bacterial reduction when exposed to varying
concentrations of SNP on the top half of the bioscaffold. (a) S.aureus (b) E .coli
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3.4 Conclusions
In this study we demonstrated the fabrication of SNP containing nanocomposite
scaffolds, with potential application is tissue regrowth and as drug eluting coatings. The
biocompatible/ bioresorbale PLLA /PEG/SNP bioscaffolds composites demonstrated significant
antimicrobial activity reducing the E.coli and S.aureus bacterial colonies by 92.5- 99.9%
respectively. Based on the antimicrobial activity experiments we recommend an antimicrobial
concentration of 800 ppm for these coatings that is efficacious to the microbes (92.5- 99.9%
reduction). Clearly, further research is needed understand the mechanism of synthesis and to
evaluate the physio-chemical properties of these materials.
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CHAPTER 4. CONCLUSIONS AND FUTURE WORK
The objective of this study is to synthesize and characterize polymer based, silver
containing nanocomposite coatings, for use in chronic indwelling medical devices, and
bioscaffolds that are both efficacious against microbes and non-cytotoxic to mammalian cells.
For PLLA coatings we synthesized novel 25-75 nm sized SNP that are biocompatible,
non-agglomerated, polydispersed, industrially relevant and of high purity to be used in the
chronic devices coatings as antimicrobial agents. The biocompatible/ bioresorbale PLLA based
coatings are embedded with the SNP and it helps reduce the E.coli and S.aureus bacterial
colonies by 99.9-99.99%. Based on the cytotoxicty and antimicrobial activity experiments we
recommend a safe antimicrobial concentration of 700 ppm for these coatings that is both
efficacious to the microbes (99.9-99.99% reduction) and non-cytotoxic (81.34% live HeLa) to
the surrounding cells. Also, increasing the SNP concentration beyond 700 ppm will only have
economic and aesthetic constrains as higher concentration does not have any better antimicrobial
or cytotoxic results. The APTS adhesion linker increases the likeliness of these coatings to be
used in actual chronic indwelling devices to help reduce the surgical site and Healthcare
Acquired Infections (HAI) that immensely burdens the healthcare providers for services
provided related to treating healthcare associated conditions.
We also demonstrated the fabrication of SNP containing nanocomposite scaffolds, with
potential application is tissue regrowth and as drug eluting coatings. The biocompatible/
bioresorbale PLLA /PEG/SNP bioscaffolds composites demonstrated significant antimicrobial
activity reducing the E.coli and S.aureus bacterial colonies by 92.5- 99.9% respectively. Based
on the antimicrobial activity experiments we recommend an antimicrobial concentration of 800
ppm for these coatings that is efficacious to the microbes (92.5- 99.9% reduction).
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Although substantial progress was made toward designing successful cast coatings and
scaffolds that demonstrate significant antimicrobial reduction other aspects of composite
synthesis and behavior must be addressed before implementation of these coatings and
bioscaffolds into therapeutic devices. The future work should address the following aspects:
4.1 PLLA Coatings
Test the antimicrobial and cytotoxic behavior of PLLA nanocomposite coatings on
simulated implantable device surfaces and compare the outcome with these results with
previously published results from glass substrate materials in order to examine the impact of
substrate composition on the physio-chemical properties the coatings.
Conduct the antimicrobial and cytotoxicity experiments in the presence serum
containing media or mammalian blood to study the behavior of the PLLA coatings when used on
cardiac or orthopedic devices.
Improve the adhesion testing method and conduct the testing on simulated implantable
devices substrates.
Conduct an in-vivo analysis of the behavior of PLLA coatings by coating chronic
indwelling devices and implanting in the devices in mammalian models to study the composites
efficacy and biocompatibility.
4.2 PLLA:PEG Bioscaffolds
Conduct EM analysis on bioscaffolds to study the distribution of SNP in the scaffolds
per volume or area to better comprehend the distribution of SNP in the scaffolds.
Explore the impact of composite composition and synthesis conditions on
nanomaterial distribution.
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Repeat the antimicrobial testing and vary the SNP concentrations above 800 ppm and
below 500 ppb.
Study the effects of adding varying concentration of SNP on the mechanical strength
and porosity of bioscaffolds through SEM and tensile testing.
Conduct mechanical test on various PLLA: PEG ratios to find the optimized blend
ratio for best antimicrobial results.
Study the release profile of SNP from the bioscaffolds by ICP-MS or ICP-OES.
Develop a methodology to determine the silver content of the nanocomposite
scaffolds.
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APPENDIX A: EXPERIMENTAL PROTOCOLS
A.1 HeLa Splitting and Seeding Procedure
A.1.a Feeding
A. Aspirate media
B. Add 5ml new DMEM-RS+3%Fetal Bovine Serum per T-25 flask. (Note: HeLa’s double
every 24hrs- Will feed 1x/wk and split 1x/wk)
C. Feed once a week for T-25 flask
A.1.b Splitting Cells (volumes are per one T-25 of confluent HeLa’s)
A.
B.
C.
D.

Aspirate media from flask to waste Stain
Rinse w/ 5 ml CMF-PBS (Ca+ & Mg+ free) and swivel in flask
Aspirate off PBS to waste
Add 5 ml of Trypsin solution
1) Wait ~10 minutes for cells to come off of the dish at room temperature. Gently
rock flask periodically and observe under microscope to make sure the cells are
detaching.

E.
F.
G.
H.
I.

Add 5 ml of DMEM-RS+3%FBS to stop trypsin action
Transfer suspension to a 50ml centrifuge tube.
Spin down the cells at 1800rpm for 5 min on the centrifuge (Eppendorf 5702)
Decant supernatant
Resuspend in 5ml of DMEM-RS+3%FBS
a) For Passaging:
i. Add 5ml fresh DMEM-RS+3%FBS to a new T-25 flask
ii. Add 3-5 drops of the cell suspension in the new T-25 flask for flask passaging.
b) For Experiment:
i. Perform cell count on 5mL of fresh DMEM+ suspended cells
ii. Use Cell Seeding Calculator to determine the amount of cell suspension and
additional fresh DMEM to add to achieve desired cell seeding density/dish
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A.2. Flow-Based Methods
A.2.a. Flow Cytometry: SYTOX Green Fluorescent Validation Protocol for Controls
A. Observe and take brightfield images of cells seeded in 12-well plate before harvesting
a. Negative control well is left as it is.
b. Induce apoptosis for positive control (2 mM H 2O2) for 4 hrs
B. For Negative and Positive control:
a) Aspirate the 0.6 ml DMEM RS (+3% FBS) cell solution from 12 well plate
b) Wash with 0.6 ml PBS (with Calcium and Magnesium)
c) Collect the DMEM and PBS solution containing the floaters in 15 ml tubes
d) Add 0.6 mL 0.25% trypsin. Allow 5-7 minutes for cells to detach from the
bottom of the dish.
e) Add 0.6 mL of DMEM-RS (+3% FBS)
f) Add trypsin and DMEM solution to 15 ml tube containing the floaters
g) Spin down at 18000 rpm on mini-spin for 5 minutes
h) Aspirate carefully using 1 mL pipettor
i) Re-suspend pallet in 1 ml PBS
j) Add 5 ul of 5 uM Sytox Green stain (Molecular Probes) (Staining steps are done
under the hood with the light off)
k) Allow 15 minutes for cells to stain with Sytox
l) Spin down at 18000 rpm on mini-spin for 5 minutes
m) Aspirate carefully using 1 mL pipettor
n) Re-suspend pallet in 250 ul 1% PFA
o) Transfer cells in solution to 5 mL cytometer tube
C. Run flow cytometry at Veterinary Medicine
a. Take labeled sheet and numbered tubes to Vet Med with cell sample tubes
covered in foil and on ice
b. Analyze samples on flow cytometer using appropriate filter settings
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A.2.b. Flow Cytometry: SYTOX Green Fluorescent Validation Protocol for Coatings
A. Harvest cells
1) Add 1 ml 2.6x106 cell/ml cell solution for 24 hrs.
2) Aspirate the 1 ml DMEM RS (+3% FBS) cell solution from pertri dishes
3) Wash with 1 ml PBS (with Calcium and Magnesium)
4) Collect the DMEM and PBS solution containing the floaters in 15 ml tubes
B. Trypsinization
1) Add 1 mL 0.25% trypsin. Allow 5-7 minutes for cells to detach from the bottom
of the dish.
2) Add 1 mL of DMEM-RS (+3% FBS)
3) Collect trypsin and DMEM solution to 15 ml tube containing the floaters
C. Centrifuge
1) Spin down 4 ml cell solution at 18000 rpm on mini-spin for 5minutes
2) Aspirate carefully using 1 mL pipettor
3) Re-suspend pallet in 1 ml PBS
D. Stain (Staining steps are done under the hood with the light off)
1) Add 5 ul of 5 uM Sytox Green stain (Molecular Probes) (Staining steps are done
under the hood with the light off)
2) Allow 15 minutes for cells to stain with Sytox
E. Centrifuge
1) Spin down PBS/Sytox Green solution at 18000 rpm on mini-spin for 5minutes
F. Fix cells
1) Re-suspend pallet in 250 ul 1% PFA
2) Transfer cells in solution to 5 mL cytometer tube
F. Run flow cytometry at Veterinary Medicine
a. Take labeled sheet and numbered tubes to Vet Med with cell sample tubes
covered in foil and on ice
b. Analyze samples on flow cytometer using appropriate filter settings
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APPENDIX B: TGA RESULTS
B.1 TGA Results to Quantify SNP Amount

The percent SNP present in the coatings is calculated based on the TGA values
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Graph processed to show the percent SNP left after the TGA experiment

Table shows the initial and final measured amount of SNP after TGA experiment on
different coating with varying concentrations of SNP (700 ppm-5000 ppm). The percent SNP
added in the PLLA coatings and the expected weight is based on the required concentration of
SNP. The final SNP weight is obtained from TGA and the values are lower than the detection
limit of the instrument.
Initial

Samples
No SNP
600 ppm
700 ppm
1000
ppm
1500
ppm
2000
ppm
5000
ppm

Final

Added
SNP(%)
0
0.06
0.07

Weight
Sample(mg)
2.025
4.363
4.202

Expected SNP
weight
0
0.0026178
0.0029414

Weight SNP
0.02168655
0.03590965
0.03246498

Percent
SNP
1.071153914
0.823018
0.772682

0.1

3.253

0.003253

0.02413368

0.742027

0.15

2.663

0.0039945

0.01847267

0.693554

0.2

2.699

0.005398

0.02399444

0.889137

0.5

2.351

0.011755

0.02852249

1.213272
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B.2 TGA Results to Quantify the Release Profile of SNP

The percent SNP present in the coatings is calculated based on the TGA values
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Graph processed to show the percent SNP left after the TGA experiment

Table shows the initial and final measured amount of SNP after TGA experiment on 700
ppm coating over a period of 6 days. The percent SNP added in the PLLA coatings and the
expected weight is based on the required concentration of SNP. The final SNP weight is obtained
from TGA and the values are lower than the detection limit of the instrument.

Initial

Samples
No SNP
700 ppm
(D1)
700 ppm
(D2)
700 ppm
(D5)
700 ppm
(D6)

Final

Added
SNP(%)
0

Weight
Sample(mg)
2.025

Initial SNP weight
0

Weight SNP
(mg)
0.02168655

Percent SNP
1.071153914

0.07

4.202

0.0029414

0.03246498

0.772682

<0.07

15.139

0.20504

1.354444

<0.07

20.388

0.2460537

1.206996

<0.07

11.754

0.1436768

1.222509
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